64441-34-5

Basic information

• Product Name: 12-(butan-2-yl)-19-hexyl-6-(1-hydroxyethyl)-9-(hydroxymethyl)-16,18-dimethyl-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentaazacyclononadecane-2,5,8,11,14,17-hexone
• Synonyms: 1-oxa-4,7,10,13,16-pentaazacyclononadecane-2,5,8,11,14,17-hexone, 19-hexyl-6-(1-hydroxyethyl)-9-(hydroxymethyl)-16,18-dimethyl-12-(1-methylpropyl)-15-(2-methylpropyl)-
• CAS NO: 64441-34-5
• Molecular Formula: C₃₂H₅₇N₅O₉
• Molecular Weight: 655.8231
• Mol File: 64441-34-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 987.8°C at 760 mmHg
• Flash Point: 551.2°C
• Density: 1.062g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.465
• CAS DataBase Reference: 12-(butan-2-yl)-19-hexyl-6-(1-hydroxyethyl)-9-(hydroxymethyl)-16,18-dimethyl-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentaazacyclononadecane-2,5,8,11,14,17-hexone(CAS DataBase Reference)
• NIST Chemistry Reference: 12-(butan-2-yl)-19-hexyl-6-(1-hydroxyethyl)-9-(hydroxymethyl)-16,18-dimethyl-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentaazacyclononadecane-2,5,8,11,14,17-hexone(64441-34-5)
• EPA Substance Registry System: 12-(butan-2-yl)-19-hexyl-6-(1-hydroxyethyl)-9-(hydroxymethyl)-16,18-dimethyl-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentaazacyclononadecane-2,5,8,11,14,17-hexone(64441-34-5)

Safety Data

• Hazardous Substances Data: 64441-34-5(Hazardous Substances Data)

Upstream product

• 694527-90-7 N-((2R,3S)-3-hydroxy-2-methylnonanoyl)-N-Me-L-Leu-L-allo-Ile-L-Ser(Bn)-OAllyl 
• 247579-05-1 (2R,3S)-3-hydroxy-2-methylnonanoic acid 
• 111-71-7 heptanal 
• 694528-18-2 4-epi-24-O-benzyl-globomycin 
• 694527-80-5 (S)-3-Benzyloxy-2-{(2S,3S)-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-4-methyl-pentanoylamino]-3-methyl-pentanoylamino}-propionic acid allyl ester 
• 694527-70-3 Boc-L-Ile-L-Ser(Bn)-OAll 
• 694527-92-9 N-((2R,3R)-3-[Boc-L-allo-Thr(TBS)-GlyO]-2-methylnonanoyl)-N-Me-L-Leu-L-Ile-L-Ser(Bn)-OAllyl 
• 742062-31-3 (S)-3-Benzyloxy-2-{(2S,3S)-2-[(S)-2-({(2R,3R)-3-[2-((2S,3S)-2-tert-butoxycarbonylamino-3-hydroxy-butyrylamino)-acetoxy]-2-methyl-nonanoyl}-methyl-amino)-4-methyl-pentanoylamino]-3-methyl-pentanoylamino}-propionic acid 
• 694527-82-7 N-((2R,3R)-3-hydroxy-2-methylnonanoyl)-N-Me-L-Leu-L-Ile-L-Ser(Bn)-OAllyl 
• 656256-01-8 N-Me-L-Leu-L-Ile-L-Ser(Bn)-OAllyl 
• 308279-65-4 (+)-(2R,3R)-3-hydroxy-2-methylnonanoic acid 
• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 694528-07-9 25-epi-24-O-benzyl-globomycin 
• 308279-70-1 N-methyl-L-leucine-L-allo-isoleucine-O-benzyl-L-serine allyl ester 

Relevant articles and documents

Solid phase synthesis of globomycin and SF-1902 A5

The syntheses of the natural lipocyclodepsipeptide-type antibiotics globomycin and SF-1902 A5 are reported, utilizing solid phase technology for the construction of the peptidic fragment and a new asymmetric methodology of epoxidation for the p

Total synthesis and NMR conformational study of signal peptidase II inhibitors, globomycin and SF-1902 A5

A stereoselective total synthesis of an antibiotic, globomycin (1a), and its congener, SF-1902 A5 (1b), was achieved. Two convergent macrocyclization routes via macrolactamization or macrolactonization to form 1a are described. A conformational study by means of NMR spectroscopy was performed in several solvents. The 1H NMR spectrum of 1a indicated that the amide proton of only the L-allo-Thr residue was involved in the hydrogen bonding. The structure in solution phase was different from the X-ray structure.

Crystal structure and total synthesis of globomycin: Establishment of relative and absolute configurations [5]

-